newsfilter
← Latest News
Business Wire·

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Collaborative clinical study will investigate a novel combination of Debio 0123, Debiopharm's potent, brain penetrant inhibitor of WEE1, and lunresertib, Repare Therapeutics' first-in-class PKMYT1 inhibitor Debiopharm